- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...
The labeling for Trulicity (dulaglutide; Eli Lilly) has been updated to include use in combination with basal insulin for adults with type 2 diabetes, following approval from the Food and Drug ...
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results